News

Asuragen Launches AmplideX® PCR/CE FMR1 Reporter*, a Fully Automated Software Solution for Accurate Sizing of the FMR1 CGG Repeat Region

Austin, Texas – Date: November 5, 2015 – Asuragen, Inc., a global molecular diagnostics company, announced today the launch of AmplideX® PCR/CEFMR1 Reporter*, an automated software system that reports accurate sizing of the FMR1 CGG repeat region directly from raw capillary electrophoresis data using AmplideX® PCR/CE FMR1 Reagents* and workflow.

This full-featured software enhances the capabilities of Asuragen’s AmplideX® FMR1 Reagents. The technology produces accurate and reliable interpretation of results in minutes—a vast improvement over manual QC and analysis that typically takes hours for larger sample sets and can create bottlenecks for laboratories that are continually striving to reduce turn-around times in producing quality results.

“AmplideX® PCR/CE FMR1 Reporter replaces generic fragment analysis software with a highly intelligent repeat sizing algorithm and user-friendly interface that is customized for fast, accurate, and consistent fragile X genotyping,” commented Gary Latham, Ph.D. Vice President of Research and Technology Development at Asuragen. “This software incorporates 6 years of feedback from the laboratory community, was trained and tested with over 1000 residual clinical samples, and includes a range of automated QC checks to deliver a reliable, efficient, and comprehensive analysis solution that matches the innovation of the AmplideX® PCR reagents it supports.”

Compatible with AmplideX® PCR/CE FMR1 PCR workflows (RUO), AmplideX® Reporter’s analysis features include automatic and robust size calibration, rapid push-button analysis, elimination of instrument -associated noise artifacts, integration of batch-level QC and run metrics, customizable minor allele sensitivity, and the ability to resolve similarly-sized saturated peaks.

Incorporating advanced visualization and annotation with simple installation and results reporting, the software offers an easy transition from the standard AmplideX® analysis workflow. Once installed, it is accessible to multiple devices on a laboratory’s network. User-interface highlights include the ability to create user roles and groups for managing accessibility, full raw data and result visualization capabilities, freedom to manually annotate peaks, and manual annotation traceability and rollback. Results are exportable in PNG and LIMS-compatible formats for simple system integration.

With the release of AmplideX® PCR/CE FMR1 Reporter*, Asuragen alleviates the constraints associated with manual interpretation and offers a solution that will allow laboratory directors to comfortably review results and manage reporting, ultimately decreasing hands-on time and improving overall turn-around time in their laboratories.

*Research Use Only. Not for diagnostic procedures.

About Asuragen
Asuragen is a global diagnostic products company delivering solutions that build knowledge and understanding of complex clinical questions. Asuragen’s application of its deep scientific heritage and molecular expertise delivers diagnostic products in oncology and genetics that provide the best answers with optimal workflows – so time can be spent delivering actionable insights, rather than searching for them. With innovative approaches to kit development and a broad range of molecular chemistries, Asuragen produces assays that ensure reproducible results. From discovery and development to regulatory support to global commercialization, we also provide a tailored approach that efficiently delivers custom and companion diagnostic products for our partners. We believe people deserve better answers. For more information, visit www.asuragen.com.

###

Back To
Top

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close